Searchable abstracts of presentations at key conferences in endocrinology

ea0022p229 | Clinical case reports and clinical practice | ECE2010

Dose of growth hormone (GH) and not IGFI level at treatment start influences treatment outcome in GH deficient adults (GHDA): Data from the NordiNet International Outcome Study (IOS)

Jorgensen Jens Otto L , Weber Matthias M , Hoybye Charlotte , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

ea0022p264 | Developmental endocrinology | ECE2010

Baseline characteristics and serum IGF1 levels in GH deficient (GHD) patients treated in the transition phase from adolescence into adulthood: data from the NordiNet International Outcome Study (IOS)

Weber Matthias M , Blankenstein Oliver , Jorgensen Jens Otto L , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Data from several clinical studies have demonstrated the benefit of GH treatment in relation to bone mineral density and body composition in young adults who received GH treatment in childhood due to GHD1–3. There are recommendations to use a higher GH dose in the transition phase compared to the GH dose required during adulthood to mimic the endogenous GH secretion4,5.Methods: Data from NordiNet IOS have been analy...